CAPRHealthcare · BiotechnologyThe 10 Wall Street analysts covering Capricor Therapeutics, Inc. hold a median 12-month price target of $25 — +212.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Capricor Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (59): The shares have been drifting up relative to others.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CAPR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +212.1% from it.
Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Sept 2026 | B. Riley Securities | Upgrade | Buy | $5.00 → $21 |
| 1 Sept 2026 | Piper Sandler | Upgrade | Overweight | — |
| 1 Sept 2026 | Piper Sandler | Upgrade | Overweight | $2.00 → $25 |
| 14 Aug 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 14 Aug 2026 | Cantor Fitzgerald | Upgrade | Overweight | $3.50 → $28 |
| 31 July 2026 | Jones Trading | Downgrade | Hold | — |
| 31 July 2026 | Jones Trading | Downgrade | Hold | — |
| 30 July 2026 | Cantor Fitzgerald | Downgrade | Neutral | $62 → $3.50 |
| 30 July 2026 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 30 July 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 30 July 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 30 July 2026 | Piper Sandler | Downgrade | Neutral | $58 → $2.00 |
| 30 July 2026 | Piper Sandler | Downgrade | Neutral | — |
| 13 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $60 |
| 13 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 13 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Mar 2026 | Piper Sandler | Reiterates | Overweight | — |
| 10 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Dec 2025 | B. Riley Securities | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAPR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Capricor Therapeutics, Inc. returned +7.1% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 46% of US stocks
Cheaper than 74% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 17% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Capricor Therapeutics, Inc. has a market value of $465.7M and an enterprise value of $318.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$129.4M.
Diluted earnings per share, trailing twelve months: $−2.45.
Free cash flow in the twelve months to 30 June 2026: −$129.8M.
Trailing P/E: −3.5×; forward P/E: −5.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Capricor Therapeutics, Inc. employs 231 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Capricor Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Capricor Therapeutics discussed HOPE-3 open-label extension data and provided an update on deramiocel for Duchenne muscular dystrophy.
Why it matters — The discussion concerns clinical data and a therapy update relevant to Capricor’s Duchenne muscular dystrophy program.
Capricor presented updated deramiocel data for Duchenne muscular dystrophy, including two-year open-label extension results from its Phase III HOPE-3 study and additional statistical analyses submitted to the FDA.
Why it matters — The update gives CAPR watchers new clinical data and analyses as an FDA decision approaches.
Capricor Therapeutics presented positive HOPE-3 open-label extension data at the 2026 World Muscle Society Congress showing that patients starting Deramiocel after a year on placebo slowed upper limb decline by 76% compared with their own prior year. Both groups showed slower decline in upper limb function than natural history predicts at 24 months, with the data included in the Deramiocel BLA major amendment and a PDUFA target action date of November 22, 2026.
Why it matters — A CAPR watcher would care because these favorable efficacy results for the lead asset Deramiocel are included in the BLA submission ahead of the November 2026 PDUFA action date, advancing the regulatory pathway for the treatment of upper limb impairment in Duchenne muscular dystrophy.
A securities class action alleges Capricor Therapeutics told investors its Phase 3 HOPE-3 results were statistically significant while allegedly omitting that the final statistical analysis plan was rewritten one day before unblinding and was never agreed to by the FDA. The release, which reminds shareholders of a September 28, 2026 lead plaintiff deadline, traces the disclosure events date by date.
Why it matters — CAPR watchers would care because the company faces a securities class action alleging it omitted key details about the HOPE-3 statistical analysis plan that could bear on the credibility of its reported Phase 3 results.
A class action lawsuit has been filed against Capricor Therapeutics and certain senior executives alleging securities fraud, following a significant drop in the company's stock price that the law firm attributes to potential violations of federal securities laws. Investors face a September 28 court deadline to contact Bleichmar Fonti & Auld LLP.
Why it matters — A securities fraud lawsuit against Capricor and its executives introduces legal and reputational risk that CAPR investors will need to monitor.
The 10 Wall Street analysts covering Capricor Therapeutics, Inc. have a median 12-month price target of $25, with estimates ranging from $7 to $54. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Capricor Therapeutics, Inc., 4 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Capricor Therapeutics, Inc. 16 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Capricor Therapeutics, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (59 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +212.1% from the last close, and Ticker Nerd's factor model ranks Capricor Therapeutics, Inc. 16 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Capricor Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $54 over the next 12 months.
Capricor Therapeutics, Inc. returned +7.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for rare diseases.
The most recent item we track (Seeking Alpha, 8 Oct 2026): "Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript". Capricor Therapeutics discussed HOPE-3 open-label extension data and provided an update on deramiocel for Duchenne muscular dystrophy.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for rare diseases. Its lead program, Deramiocel, is an allogeneic cardiac-derived cell therapy being advanced for Duchenne muscular dystrophy, a severe muscle-wasting disorder with significant unmet medical need. The company also develops engineered exosomes through its StealthX platform, which is designed to deliver nucleic acids, proteins, and small molecules for applications in vaccinology and other therapeutic areas. Capricor Therapeutics operates in the healthcare and life sciences sector, where its work spans regenerative medicine, rare-disease treatment, and next-generation biologics. The company’s current portfolio centers on advanced clinical and preclinical programs that aim to address complex conditions through targeted biological mechanisms rather than traditional small-molecule approaches.
CEO Dr. Linda Marbán Ph.D. · 231 employees · United States · https://www.capricor.com
